Sabine C. Linn

17.3k citations

231 papers · 9.1k indexed · 1 hit paper · h-index 48

Cancer Research top 0.2%
- Breast Cancer Treatment Studies 84
- Cancer Genomics and Diagnostics 32
Oncology top 0.5%
- HER2/EGFR in Cancer Research 52
- Cancer Treatment and Pharmacology 33
Pulmonary and Respiratory Medicine top 0.5%
- Advanced Breast Cancer Therapies 27
Genetics top 1%
- Estrogen and related hormone effects 42
- BRCA gene mutations in cancer 31
Pathology and Forensic Medicine top 1%
- Breast Lesions and Carcinomas 20

Co-authors: Marc J. van de Vijver Michael Hauptmann Jelle Wesseling Karin Beelen Hugo M. Horlings Wilbert Zwart Emiel J. Rutgers Wolter J. Mooi
Cited by: Cancer Research Oncology Pulmonary and Respiratory Medicine
Journals: Proceedings of the National Academy of Sciences (1 paper)The Lancet (1 paper)Nature Communications (1 paper)
Partner nations: Netherlands United States Germany

In The Last Decade

Sabine C. Linn

222 papers receiving 8.9k citations

Hit Papers

align trajectories log scale

Peers

Countries citing papers authored by Sabine C. Linn

Since Specialization

Citations

This map shows the geographic impact of Sabine C. Linn's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Sabine C. Linn with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Sabine C. Linn more than expected).

Fields of papers citing papers by Sabine C. Linn

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Sabine C. Linn. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Sabine C. Linn. The network helps show where Sabine C. Linn may publish in the future.

Co-authorship network

The 25 scholars most cited alongside Sabine C. Linn, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Sabine C. Linn Line = papers co-authored together Sabine C. Linn links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work
1	Worse prognosis for breast cancer diagnosed in advanced pregnancy and shortly postpartum: an update of the Dutch pregnancy-associated breast cancer cohort Breast Cancer Research and Treatment ·Carsten F J Bakhuis,Stefan Preković,Britt B.M. Suelmann,Janneke Verloop,Pieter J. Westenend,Sabine C. Linn,P. J. van Diest,Elsken van der Wall,Carmen van Dooijeweert	2025	1
2	The prognostic and predictive effect of body mass index in hormone receptor-positive breast cancer JNCI Cancer Spectrum ·S W M Lammers,Sandra M. E. Geurts,Irene E.G. van Hellemond,Astrid C P Swinkels,Carolien H. Smorenburg,Maurice J.C. van der Sangen,Judith R. Kroep,Hiltje de Graaf,Aafke H. Honkoop,Frans Erdkamp,W Roos,Sabine C. Linn,Alexander L.T. Imholz,Marjolein L. Smidt,Ingeborg J. H. Vriens,Vivianne C. G. Tjan‐Heijnen	2023	4
3	Extended adjuvant aromatase inhibition after sequential endocrine therapy in postmenopausal women with breast cancer: follow-up analysis of the randomised phase 3 DATA trial EClinicalMedicine ·Vivianne C. G. Tjan‐Heijnen,S W M Lammers,Sandra M. E. Geurts,Ingeborg J. H. Vriens,Astrid C P Swinkels,Carolien H. Smorenburg,Maurice J.C. van der Sangen,Judith R. Kroep,Hiltje de Graaf,Aafke H. Honkoop,Frans Erdkamp,W Roos,Sabine C. Linn,Alexander L.T. Imholz	2023	11
4	Daily Oral Ibandronate With Adjuvant Endocrine Therapy in Postmenopausal Women With Estrogen Receptor–Positive Breast Cancer (BOOG 2006-04): Randomized Phase III TEAM-IIB Trial Journal of Clinical Oncology ·S.B. Vliek,Iris Noordhoek,Elma Meershoek‐Klein Kranenbarg,Annelot G.J. van Rossum,Vincent O. Dezentjé,Agnes Jager,J.W. Esmeralda Hokken,Hein Putter,Annette W.G. van der Velden,Mathijs P. Hendriks,Sandra D. Bakker,Yvonne E A van Riet,Vivianne C. G. Tjan‐Heijnen,Johanneke E.A. Portielje,Judith R. Kroep,J.W.R. Nortier,Cornelis J.�H. van de Velde,Sabine C. Linn	2022	8
5	Fertility preservation for women with breast cancer: a multicentre randomized controlled trial on various ovarian stimulation protocols Human Reproduction ·Eva Balkenende,Taghride Dahhan,C. C. M. Beerendonk,Kathrin Fleischer,Dominic Stoop,Annelies M. E. Bos,Cornelis B. Lambalk,R. Schats,J Smeenk,L Louwe,Astrid EP Cantineau,Jan Peter de Bruin,Sabine C. Linn,Fulco van der Veen,Madelon van Wely,Mariëtte Goddijn	2022	24
6	FER regulates endosomal recycling and is a predictor for adjuvant taxane benefit in breast cancer Cell Reports ·Sandra Tavares,Nalan Liv,Milena Pasolli,Mark Opdam,Max A. K. Rätze,Manuel Saornil,Lilian Sluimer,Rutger C.C. Hengeveld,Robert van Es,Erik van Werkhoven,Harmjan R. Vos,Holger Rehmann,Boudewijn Burgering,Hendrika M. Oosterkamp,Susanne M.A. Lens,Judith Klumperman,Sabine C. Linn,Patrick W.B. Derksen	2022	7
7	Characterization of Oligometastatic Disease in a Real-World Nationwide Cohort of 3447 Patients With de Novo Metastatic Breast Cancer JNCI Cancer Spectrum ·Tessa G. Steenbruggen,Michael Schaapveld,Hugo M. Horlings,Joyce Sanders,Sander J Hogewoning,Esther H. Lips,Marie-Jeanne TFD Vrancken Peeters,Niels F. M. Kok,T. Wiersma,Laura J. Esserman,Laura van ‘t Veer,Sabine C. Linn,Sabine Siesling,Gabe S. Sonke	2021	18
8	Adjuvant Aromatase Inhibitors or Tamoxifen Following Chemotherapy for Perimenopausal Breast Cancer Patients JNCI Journal of the National Cancer Institute ·Gwen Dackus,Katarzyna Jóźwiak,Gabe S. Sonke,Elsken van der Wall,P. J. van Diest,Sabine Siesling,Michael Hauptmann,Sabine C. Linn	2021	5
9	The NF-κB Pathway Promotes Tamoxifen Tolerance and Disease Recurrence in Estrogen Receptor–Positive Breast Cancers Molecular Cancer Research ·Irida Kastrati,Stacey E. P. Joosten,Svetlana E. Semina,Luis H. Alejo,Svitlana D. Brovkovych,Joshua D. Stender,Hugo M. Horlings,Marleen Kok,Elaine T. Alarid,Geoffrey L. Greene,Sabine C. Linn,Wilbert Zwart,Jonna Frasor	2020	38
10	PI3K pathway protein analyses in metastatic breast cancer patients receiving standard everolimus and exemestane Journal of Cancer Research and Clinical Oncology ·Dinja T. Kruger,Mark Opdam,Vincent van der Noort,Joyce Sanders,Michiel Nieuwenhuis,Bart de Valk,Karin Beelen,Sabine C. Linn,Epie Boven	2020	6
11	Comprehensive trends in incidence, treatment, survival and mortality of first primary invasive breast cancer stratified by age, stage and receptor subtype in the Netherlands between 1989 and 2017 International Journal of Cancer ·Daniël J. van der Meer,Iris Kramer,Marissa C. van Maaren,P. J. van Diest,Sabine C. Linn,John H. Maduro,Luc J. A. Strobbe,Sabine Siesling,Marjanka K. Schmidt,Adri C. Voogd	2020	51
12	Comparative Cistromics Reveals Genomic Cross-talk between FOXA1 and ERα in Tamoxifen-Associated Endometrial Carcinomas Cancer Research ·Marjolein Droog,Ekaterina Nevedomskaya,Yongsoo Kim,Tesa Severson,Koen D. Flach,Mark Opdam,Karianne Schuurman,Patrycja Gradowska,Michael Hauptmann,Gwen Dackus,Harry Hollema,Marian J.E. Mourits,Petra M. Nederlof,Hester van Boven,Sabine C. Linn,Lodewyk F.A. Wessels,Flora E. van Leeuwen,Wilbert Zwart	2016	26
13	The effect of trastuzumab-based chemotherapy in small node-negative HER2-positive breast cancer Breast Cancer Research and Treatment ·Mette S. van Ramshorst,Margriet van der Heiden‐van der Loo,Gwen Dackus,Sabine C. Linn,Gabe S. Sonke	2016	27
14	High XIST and Low 53BP1 Expression Predict Poor Outcome after High-Dose Alkylating Chemotherapy in Patients with a BRCA1 -like Breast Cancer Molecular Cancer Therapeutics ·Philip C. Schouten,Marieke A. Vollebergh,Mark Opdam,Martijn Jonkers,Martin Lodén,Jelle Wesseling,Michael Hauptmann,Sabine C. Linn	2015	43
15	DNA repair deficiency biomarkers and identification of ER-positive breast cancer patients who may benefit from veliparib/carboplatin: Results from the I-SPY 2 trial. Journal of Clinical Oncology ·Laura van’t Veer,Laura Esserman,Ashish Sanil,Annuska M. Glas,Tessa Severson,Sabine C. Linn,Lamorna Brown Swigart,Gillian L. Hirst,I-SPY Investigators,Olufunmilayo I. Olopade,Hope S. Rugo,Don Berry,Denise M. Wolf,Christina Yau	2015	1
16	Breast Cancers with a BRCA1 -like DNA Copy Number Profile Recur Less Often Than Expected after High-Dose Alkylating Chemotherapy Clinical Cancer Research ·Philip C. Schouten,Frederik Marmé,Sebastian Aulmann,Hans‐Peter Sinn,Hendrik F. van Essen,Bauke Ylstra,Michael Hauptmann,Andreas Schneeweiß,Sabine C. Linn	2014	30
17	Hallmarks of Aromatase Inhibitor Drug Resistance Revealed by Epigenetic Profiling in Breast Cancer Cancer Research ·Maurice P.H.M. Jansen,Theo Knijnenburg,Esther A. Reijm,Iris Simón,Ron Kerkhoven,Marjolein Droog,Arno Velds,Steven Van Laere,Luc Dirix,Xanthippi Alexi,John A. Foekens,Lodewyk F.A. Wessels,Sabine C. Linn,Els M.J.J. Berns,Wilbert Zwart	2013	57
18	Gene Expression Patterns and Gene Copy Number Changes in Dermatofibrosarcoma Protuberans American Journal Of Pathology ·Sabine C. Linn,Robert B. West,Jonathan R. Pollack,Shirley Zhu,Tina Hernandez‐Boussard,Torsten O. Nielsen,Brian P. Rubin,Rajiv M. Patel,John R. Goldblum,David Siegmund,David Botstein,Patrick O. Brown,C. Blake Gilks,Matt van de Rijn	2003	107
19	Expression of drug resistance proteins in breast cancer, in relation to chemotherapy International Journal of Cancer ·Sabine C. Linn,Herbert M. Pinedo,J van Ark-Otte,Paul van der Valk,Klaas Hoekman,Aafke H. Honkoop,Jan B. Vermorken,Giuseppe Giaccone	1997	7
20	A patient with adrenocortical carcinoma: characterization of its biological activity and drug resistance profile. PubMed ·N Feller,Klaas Hoekman,Catharina M. Kuiper,Sabine C. Linn,Henk M.W. Verheul,B.G. Wolthers,C. Popp‐Snijders,Herbert M. Pinedo	1997	9

About Sabine C. Linn

Sabine C. Linn is a scholar working on Cancer Research, Oncology and Genetics, having authored 231 papers that have together received 9.1k indexed citations. Recurring topics across this work include Breast Cancer Treatment Studies (84 papers), HER2/EGFR in Cancer Research (52 papers), Estrogen and related hormone effects (42 papers), Cancer Treatment and Pharmacology (33 papers), Cancer Genomics and Diagnostics (32 papers), BRCA gene mutations in cancer (31 papers), Advanced Breast Cancer Therapies (27 papers) and Breast Lesions and Carcinomas (20 papers). The work is most often cited by research in Cancer Research (3.4k citations), Oncology (4.7k citations) and Pulmonary and Respiratory Medicine (2.4k citations). Sabine C. Linn has collaborated with scholars based in Netherlands, United States and Germany. Frequent co-authors include Marc J. van de Vijver, Michael Hauptmann, Jelle Wesseling, Karin Beelen, Hugo M. Horlings, Wilbert Zwart, Emiel J. Rutgers, Wolter J. Mooi, Ralph Meuwissen and Anton Berns. Their work appears in journals such as Proceedings of the National Academy of Sciences, The Lancet and Nature Communications.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact